On December 5, 2025, EY officially announced the laureates of the EY Entrepreneur Of The Year™ 2025 awards. Among the honorees, 12 outstanding entrepreneurs from Mainland China and Hong Kong/Macao were recognized for their exceptional leadership and impact.Dr. Lu Xianping, Chairman and General Manager of Chipscreen Biosciences, was honored with this year's Life Sciences and Healthcare Industry Award and the EY Entrepreneur Of The Year 2025- Mainland China Award in recognition of his exceptional achievements in pioneering original new drugs and his outstanding contributions to advancing the development of China's innovative drug regulatory system and industrial ecosystem. He will now represent Mainland Chinese entrepreneurs in the global competition for the prestigious EY World Entrepreneur of the Year title.

As the only entrepreneur from Mainland China to receive this honor this year, Dr. Lu Xianping stated at the award ceremony: As a scientist in the field of life sciences, I will live up to this era and our society. For a better life, I am committed to safeguarding lives through source innovation!

As a pioneer in China's original new drug sector, Dr. Lu has steadfastly pursued an independent First-in-class innovation path despite the industry challenges of high investment, long cycles, and high risks in drug R&D. His efforts resulted inthe successful development of Chidamide, China's first original anti-tumor chemical new drug, and Chiglitazar Sodium, the world's first approved PPAR pan-agonist.

Beyond scientific innovation, Dr. Lu has actively advanced improvements to China's innovative drug review and approval processes, healthcare reimbursement systems, and capital market reforms. With unwavering pioneering spirit, scientific dedication, and deep involvement in institutional innovation, he has contributed a highly significant Chipscreen Model to the development of China's pharmaceutical industry, exemplifying a science-based, patient-centric entrepreneurial ethos. Under the leadership of Dr. Lu Xianping, Chipscreen Biosciences has built a globally competitive product pipeline through its integrated technology platform combining AI-assisted design and chemogenomics, striving to address global challenges with Chinese ingenuity..

In 2025, Chidamide was featured in 47 presentations at prestigious international academic forums such as ASCO, ESMO, EHA, and ASH. Furthermore, the Phase II clinical trial results of Chiglitazar Sodium monotherapy for metabolic dysfunction-associated steatohepatitis (MASH) were published in Hepatology, a top-tier international journal in hepatology. Its development journey was also documented in the book Drug Discovery Stories, published by the renowned international publisher Elsevier.

The EY Entrepreneur Of The Year award is one of the world's most influential international business accolades. Since its inception in 1986, it has expanded to 79 countries and regions globally. The award aims to recognize entrepreneurs whose extraordinary vision, exceptional leadership, and innovative spirit have profoundly impacted industry development and social progress..

The award was officially introduced to China in 2006. This year marks the 20th anniversary of the award's presence in Mainland China, Hong Kong, and Macao. Under the theme Two Decades of Staying True to the Original Aspiration, Forging Ahead in the New Era, the award seeks to discover and honor outstanding entrepreneurs who demonstrate the courage to innovate, a sense of responsibility, a commitment to excellence, and steadfast dedication to their original mission, thereby making leading contributions to China's private economy in the new era.